Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)

Daniel M. Geynisman, Philip H. Abbosh, Eric Ross, Matthew R. Zibelman, Pooja Ghatalia, Fern Anari, James R. Mark, Lambros Stamatakis, Jean H. Hoffman-Censits, Rosalia Viterbo, Richard E. Greenberg, Thomas M. Churilla, Eric M. Horwitz, Mark A. Hallman, Marc C. Smaldone, Robert Uzzo, David Y.T. Chen, Alexander Kutikov, Elizabeth R. Plimack

Open source

DOI: 10.1200/jco-24-01214
Published: 2025-03-20
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-24-01214,
  title = {Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)},
  author = {Daniel M. Geynisman and Philip H. Abbosh and Eric Ross and Matthew R. Zibelman and Pooja Ghatalia and Fern Anari and James R. Mark and Lambros Stamatakis and Jean H. Hoffman-Censits and Rosalia Viterbo and Richard E. Greenberg and Thomas M. Churilla and Eric M. Horwitz and Mark A. Hallman and Marc C. Smaldone and Robert Uzzo and David Y.T. Chen and Alexander Kutikov and Elizabeth R. Plimack},
  year = {2025},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-24-01214},
  url = {https://doi.org/10.1200/jco-24-01214}
}

RIS

TY  - JOUR
TI  - Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)
AU  - Daniel M. Geynisman
AU  - Philip H. Abbosh
AU  - Eric Ross
AU  - Matthew R. Zibelman
AU  - Pooja Ghatalia
AU  - Fern Anari
AU  - James R. Mark
AU  - Lambros Stamatakis
AU  - Jean H. Hoffman-Censits
AU  - Rosalia Viterbo
AU  - Richard E. Greenberg
AU  - Thomas M. Churilla
AU  - Eric M. Horwitz
AU  - Mark A. Hallman
AU  - Marc C. Smaldone
AU  - Robert Uzzo
AU  - David Y.T. Chen
AU  - Alexander Kutikov
AU  - Elizabeth R. Plimack
PY  - 2025
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-24-01214
UR  - https://doi.org/10.1200/jco-24-01214
ER  -

APA

Geynisman, D. M., Abbosh, P. H., Ross, E., Zibelman, M. R., Ghatalia, P., Anari, F., Mark, J. R., Stamatakis, L., Hoffman-Censits, J. H., Viterbo, R., Greenberg, R. E., Churilla, T. M., Horwitz, E. M., Hallman, M. A., Smaldone, M. C., Uzzo, R., Chen, D. Y., Kutikov, A., & Plimack, E. R. (2025). Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01214

Source records

crossref · retrieved 2026-11-07T13:54:43.211Z